Anda di halaman 1dari 28

1

Escozine for Pets


TM

New frontier in pet oncological treatment;


based on blue scorpion venom, which has
been used for years to to treat humans
with cancer in many countries
Revolutionary new drug, with proven
ability to reduce tumor size- no signs of
toxicity or complications observed during
clinical use.
Can be easily administered, has healthy
profit margins, market acceptance will be
quick, translating to high sales growth

The Problem
Pets are living longer than ever before, making them
more susceptible to developing cancer
Cancer is the # 1 disease related cause of death
for dogs in the U.S.
Cancer accounts for almost 50% of deaths in pets
older than 10 years
Average costs to treat lymphoma in pets is
$2,000-most owners will rather watch their pets
die than pursue treatment
1 in 4 dogs and 1 in 5 cats will develop cancer in
their lifetime
Dogs get cancer at about the same rate as
humans

Current Solutions

The most common treatment modalities used to combat cancer include: Surgical treatment, Chemotherapy,
Radiation Therapy and Immunotherapy.

PALLADIA is the first and only FDA-approved drug for canine cancer. While it is administered orally, it
is still technically chemotherapy. Side effects may include low white blood cell counts, diarrhea,
vomiting, lethargy, fatigue, and stomach ulceration.
Low response rate, roughly 40% of dog with mast cell tumors will actually respond to the drug, while
the majority do not.
(US National Library of Medicine National Institutes of Health)

Market Opportunity
In 2015, $60.28 billion was spent
on pets in the U.S.-26% on vet
care services
Food
23.05
Supplies/OTC
Medicine
14.28
Vet Care
15.42
Live
animal purchases
Pet2.12
Services: grooming & boarding
5.41

Breakdown: Spending on
Pets in 2015 ($ billions)

Market Opportunity
Current treatment methods are quite expensive and
not totally safe for pets
Initial visit, including diagnosis, discussion of
prognosis and a treatment plan
$200+
Major surgery to remove a tumour deep in the
body, or that requires reconstruction
$1500+
Chemotherapy (depends on the size of the
dog)
ranges from $200 to $2,000 and up
Radiation therapy
ranges from $2,000 to $6,000
Pain medications
$25 to $50 a
month.

CASE REPORT

Prohibitive treatment costs means some


owners have no choice but to let their
pets die rather than seeking further
treatment

I
Amount spent: $3,000
Posted by : Irena in Vancouver. CA,
Breed : Shepxgolden
Treatment : Owner Took no action/did
not seek further
treatment

Posted
: March 3rd, 2011
08:03 PM
Cancer Type : Intestinal

My beautiful 12 years boy started vomiting and lost 20 lb. Bl.test


2x, great, extray stomach , lungs great. Everything was great, but
Sky was starved to death in front my eyes. 2 months nightmare,
cry from pain, cannot eat, horrible. Ultrasound mass tumor.
Surgery, just open his belly told me cancer is in lymp.nodes, have
one months to live if most. My boy suffered so much, so much , I
let him go, when sleep on oper, table, hug him and let him go. I
cant let him suffer more. Was very, just like that, on and off 2
months.

Introducing a new generation of HP


(high potency) veterinary cancer medications and nutraceuticals

NEYMAR BLACK
Entertainment

Escozine for Pets

Escozine for Pets


Immunity Booster

Escozine for Pets Supplements


and Nutraceuiticals

Escozine for Pets


Escozine for Pets is a an innovative
polarized, potentiated bio-active peptide
extracted
from
the
Blue
Scorpion
(Rhopularus Princeps)
Induces apoptosis on a variety of cancer
cells by a pattern of DNA fragmentation
It is based on the same-patented formula of
Escozine used for the treatment of cancer
in humans but is amplified through
polarization technology

10

11

ESCOZINE FOR PETSTM


inhibits blood
vessel growth (angiogenesis) in solid
tumors.
Chlorotoxin
blocks
transmembrane fluxes of chlorine and regulates
the adjusting of cell growth, cell division
and metastasis thereby inducing tumor
cell death (apoptosis). The regulating of
activity of the potassium (K+) 3-4 kDa,
sodium (N+) 6-8 kDa and chloride (CL+)
voltgate ionic channels of the tumor cells
leads to growth arrest and causes cell
death (apoptosis); additionally, calcium
dependent potassium channels inhibit
growth of other cancer cells.
Innovation Therapeutics (2015). Review of Pre-clinical & Clinical
data and Scorpion Venom studies to further support clinical
research & development and registration of EscozineTM for Pet
Life.

Escozine
for
Pets
Escozine for Pets has a number

of
advantages over current treatment

It can be used along with the


regimens
traditional
forms
of
cancer
treatment
Sensitizes cancer cell resistance,
thereby increasing the efficacy of
other drugs used in treating the
cancer in the animal.
Has selective binding preferences
with malignant cells .
Easy administering orally
Cost effective

12

Escozine - A Breakthrough in Cancer


Treatment and Prevention

Documented clinical observations :


Reduction in pain
Enhancement of the recipients immune-system
Reduction of cancerous cell multiplication
Inhibition of new blood vessel formation from pre-existing
cancerous cells.
Improvement in quality of sleep
Reduction of inflammation
Dramatic
reduction
in
the
painful
side-effects
of
chemotherapy and radiation treatment
Improvement of appetite

13

Testimonials

It has now been almost 1 year and 5


months since Bootsie's lung tumor
diagnosis and 1 year and 3 months of
being on Escozine. I can't thank the
PetLife team and our vet, Dr Mitchell, for
making this and introducing it to us. I
never imagined she would still be with
us today. If you saw and interacted with
Bootsie, you wouldn't even know she
had a tumor. She is an up beat 16 year
old cat (if there is such a thing) who still
loves sitting by the window sun bathing
and watching the birds, playing and
grooming her sisters (2 younger cats),
and snugglinganonymous
with my husband and me.

When we started Bootsie on the


Escozine, we were only hoping for it to
help her lung tumor, however, we think it
may be helping other health conditions
she has. For the last 5 or so years now,
Bootsie has had kidney disease as well.
Just 2 months ago (Oct 2015) when our
doctor did a routine blood panel check
and urine check for her kidneys, her
results look the best they've been in a
few years! We are amazed at what this
is doing for our baby's health. For a then
15 year old cat who was given only 3
months to live now being 16 years old
and making it 1 year and 5 months past
diagnosis is a anonymous
true miracle for us. Thanks
again, Escozine!

14

Testimonials

My 9-year-old toy poodle, Ophelia, developed multiple breast lumps.


She's been under the care of Dr. Joel Beth Mitchell of Aventura
Animal Hospital and Resort. Dr. Mitchell had to perform several
extensive surgeries in order to remove them all. Some biopsy
results came back as low-grade carcinomas. We were devastated.
Those were very dark times. Dr. Mitchell, whose opinion we hold in
the highest regard, told us about Escozine. Some of her cancer
patients who had had grim prognoses in the past, are alive and well,
and they are taking Escozine. I was intrigued and encouraged,
started reading a lot of literature on blue scorpion venom and
decided to try it. I'm so glad I did. Ophelia has recovered remarkably
well after very difficult surgeries. She's happy, full of energy and
does not show any signs of sickness anymore, thank G-d. Escozine is
very easy to administer. I only wish I could teach Ophelia to take it
herself. Very grateful to Dr. Mitchell and Escozine team. Please
continue your research and development. It benefits animals and
people as well. Thank you! anonymous

15

Revenue Model

16

Step 1. It is important that we first


generate interest in Escozine for PetsTM. We
will generate buzz through online articles,
social media posts, videos, and during
animal events
Step 2. An animal specialist analyzes the
needs of the animal and prescribes Escozine
for Pets alone or in combination with other
treament
Step 3: Management of pet condition. The
pet is monitored to ensure it is responding
to treatment.

anonymous

Step 4: Encourage owners whose pets have


been cured to spread word about Escozine

Revenue Growth to be Driven


by New Customer Acquisitions

Expanding into new geographical markets. Each year, the company will open a new
distribution center in a strategic geographical market i.e. India, Latin America and others
Ease of availability, cost effectiveness, easy administering, and aggressive brand building
activities, will drive sales increases at a fast pace, year on year

17

Competition
Competitor

18

Description

Company/Drug
Conditionally approved by FDA in 2010, Kinavet-CA1, is a tyrosine kinase inhibitor. It is used to
treat mast cell tumors, a common form of cancer that affects dogs. Kinavet-CA1 works in three
ways: by blocking the survival signal of the tumor cells, which may induce disappearance of the
tumor, by preventing tumor growth and preventing the spread of tumor cells (metastasis).
Paccal VetCA1 has been granted conditional approval by the FDA for the treatment of: nonresectable stage III, IV or V mammary carcinoma in dogs that have not received previous
chemotherapy, or radiotherapy and resectable and non-resectable squamous cell carcinoma in
dogs that have not received previous chemotherapy, or radiotherapy.
The only drug fully approved by the FDA for the treatment of cancer in canines is Palladia.
Palladia is a prescription-only therapy is used to treat grade II or III recurrent cutaneous mast
cell tumors with or without regional lymph node involvement. It works by blocking the activity of
key receptors important in the development of blood vessels that supply tumors, as well as
receptors vital for tumor survival.

19

Competitive Advantage
Esozine for Pets

will succeed against competition in a number

of areas:

Toxic cancer treatments for pets creates pent up


demand for PetLifes non-invasive products.
Patent Protection: PetLife has an exclusive license and
rights to the patent on Polarized Scorpion Venom
Projected rapid sales growth and high gross margins:
gives room to adjust pricing for competitiveness
Complementary treatment properties: Escozine for
PetsTM can be used as complementary treatment to
chemotherapy drugs

20

Positioning
We will position Escozine for Pets in
the market as a non-invasive, cost
effective ($249 cost of treatment per
patient for each month) drug in the
pet oncology market

Escozine
Surgery
Chemotherapy
Radiation
Therapy

Marketing and Growth Strategy

21

Petlifes primary marketing strategy is premised on


building brand awareness, and rapid penetration of
strategic geographical markets.
Infomercials Both online and offline to
educate pet owners
about cancer risk in
Pets.
Product bundling
- market Escozine for Pets
and supplements as treatments that symbiotically work
with one another and can effectively treat cancer in
pets.

Multi-local launches-Running online and offline


launches for each new geographical market. This will
help localize and establish PetLifes brand and products,
and help improve Google search rankings

22

Partnership is our winning strateg


PetLife will sell Escozine for PetsTM to veterinarians using multiple
respected veterinarian centers of influence to promote the product.
Incentives will be provided to veterinarians to market the companys
products.
Independent veterinarians will voluntarily help the company conduct
clinical trials of its drugs.

Financial Projections

23

PetLife 5-Year Highlights

Escozine for Pets line of nutraceutical


will launch in 2017, helping the business
immediately start generating cash.

High product margins and slow increase


in operating costs against sales.

High product margins, and fast revenue growth across all product categories (more than 100% sales growth in
the first three years) will see the company in a healthy cash positition

Investment Proposal

24

Petlife Pharma is seeking to raise $8.5 million through a private placement offering to fund
the approval and launch of Escozine for Pets. The initial part of our raise is $400,000.

$6.88 million is earmarked for Multi-Center


Clinical Studies for Escozine for Pets. These
studies will include testing of safety and
toxicity as well as determining appropriate
doing parameters. It is estimated that these
studies can be completed in 18-22 months
Once initial safety and toxicity studies are
performed the Company may consider applying
for Compassionate Use approval in certain
animal cancers. This could occur in a few as 9
months.

25

Investment Proposal

In return for $8.5 million, the company shall issue 17,000,000 shares to investors, which are
equal to a 22.5% stake in the company after dilution.

Common
Shares

Commo
n
Options

Phase
One
$
Invested

Phase
One
Shares

Phase
One
%

Fully Diluted
Shares

% Fully
Diluted

Shareholder
Irrevocable de
Fidecomison Confianza
General De Familiar
Irrevocable

30,700,00
0

$0

0.0% 30,700,000

Grand Street Ventures

5,700,000

$0

0.0% 5,700,000

Shareholders with
under 5%

11,083,65
2

$0

0.0% 11,083,652

14.6%

Elite International
Partners, Inc.

11,203,12
5

$0

0.0% 11,203,125

14.8%

100.0% 17,000,000

22.5%

Phase One Investors


#1

17,000,00
$8,500,000 0

40.6%

7.5%

26

Investment Proposal
Value per Share ($) and Market Cap ($ million)

High Free Cash Flow generating potential


Net Profit Margins

Net Profit Margin

Value per Share

Market Cap ($ million)

27

Key Milestones

Sources
DRESSLER, D. (2009). Palladia, First Dog Cancer Drug FDA Approved But Not Great. Retrieved May 29,
2016, from
http://www.dogcancerblog.com/blog/first-dog-cancer-drug-fda-approved-but-not-great/
The Ins and Outs of Cancer in Pets. (2016). Retrieved May 29, 2016, from
http://www.vosrc.net/blog/the-ins-and-outs-of-cancer-in-pets/
How Much Does Dog Cancer Treatment Cost? - CostHelper.com. (n.d.). Retrieved May 29, 2016, from
http://pets.costhelper.com/dog-cancer-treatment.html
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate
(SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or
distant) mast cell tumor following surgical excision. (2009, June/July). Retrieved May 29, 2016, from
http://www.ncbi.nlm.nih.gov/pubmed/19470739
Pet Cancer Facts and Figures. (n.d.). Retrieved May 29, 2016, from
http://www.petinsurance.com/healthzone/pet-articles/pet-infographics/Pet-Cancer-Facts-and-Figures-In
fographic.aspx
Pet Industry Market Size & Ownership Statistics. (n.d.). Retrieved May 29, 2016, from
http://www.americanpetproducts.org/press_industrytrends.asp
Rusk, A., Dr. (n.d.). Cancer is the leading cause of death in dogs and cats. Retrieved May 29, 2016, from
http://www.vetcontact.com/en/art.php?a=773

28